Specifications
Applications
Application Notes
Suitable for use in PK bridging ELISA.
We recommend the following for sandwich ELISA (Capture - Detection):
CABT-ZB258 - CABT-ZB259
Recommended Working Concentration: 0.05-1 μg/ml
General Notes
We recommend the following antibody pair to develop a pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB258 - CABT-ZB259
CABT-ZB258 is recommended for use as a capture antibody when paired with CABT-ZB259 as a detection antibody.
Ustekinumab with trade name Stelara, is an FDA-approved drug to Crohn's disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis, targeting both interleukins (IL)-12 and IL-23. Ustekinumab is a fully human immunoglobulin G1 kappa mAb that binds to IL-12 and IL-23. Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor β1 subunit of the IL-12 and IL-23 receptor complexes, thereby disrupting the proinflammatory pathway.
Images
ELISA, PK study
CABT-ZB258 binds with Ustekinumab. While the antibody does not recognize the human lgG Fc fragment (data not shown).
Coating antigen: Ustekinumab, 1 μg/ml.
CABT-ZB258 dilution start from 1,000 ng/ml, EC50=30.08 ng/ml.
ELISA, PK study
Standard curve of Ustekinumab Sandwich ELISA. The Ustekinumab Sandwich ELISA assay is developed by using CABT-ZB258 and CABT-ZB259 as capture and detection antibodies, respectively. In this ELISA assay, CABT-ZB259 was labeled with Biotin.
The sensitivity of detecting Ustekinumab is up to 0.87 ng/ml.
Target
Alternative Names
Mouse monoclonal antibody to Ustekinumab/Stelara; CNTO 1275; Stelara; Ustekinumab
Custom Antibody Labeling
We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody.
Learn More
Citations
Have you cited CABT-ZB258 in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Strober, BE; Crowley, JJ; et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. BRITISH JOURNAL OF DERMATOLOGY 165:661-668(2011).
Nast, A; Sporbeck, B; et al. Which Antipsoriatic Drug Has the Fastest Onset of Action?: Systematic Review on the Rapidity of the Onset of Action. JOURNAL OF INVESTIGATIVE DERMATOLOGY 133:1963-1970(2013).
COA
Certificate of Analysis
